Dusseldorf - Delayed Quote EUR

Novo Nordisk A/S (NOVA.DU)

82.00

+1.00

+(1.23%)

At close: 7:31:04 PM GMT+1

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programm

GlobeNewswire 3 days ago

NONOF

NVO
Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK

The latest investor updates on stocks that are trending on Monday

Yahoo Finance UK 3 days ago

^FTSE

BABA

BABAF
3 Intriguing Stocks That May Be Trading At An Estimated 13.8% Below Intrinsic Value

As global markets continue to react positively to recent political developments and economic indicators, major indices like the S&P 500 have reached new record highs, driven by optimism around trade policies and AI investments. Amidst this buoyant market environment, identifying stocks that are potentially undervalued can be a strategic move for investors looking to capitalize on discrepancies between market price and intrinsic value.

Simply Wall St. 3 days ago

NONOF

NVO

SNCAF
Stock Market Today: Indexes Close Near Day's Lows; Nvidia Ends Winning Streak, Tesla Reverses Lower (Live Coverage)

Dow Jones dragged along in the stock market today. The Nasdaq composite sank below the 20,000 level and small caps joined the sell-off.

Investor's Business Daily 6 days ago

NONOF

NVO

ISRG
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

Investor's Business Daily 6 days ago

NONOF

NVO

LLY
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Investor's Business Daily 6 days ago

NONOF

NVO

ALUR
Novo Nordisk, Twilio, Texas Instruments: Market Minute

Yahoo Finance reporter Brooke DiPalma breaks down the latest stock market developments as part of this morning's Market Minute. Novo Nordisk (NVO) shares surged after the company reported breakthrough weight-loss drug trial results. The pharmaceutical company's injectable GLP-1 Amycretin medication demonstrated an impressive average weight loss of 22% over 36 weeks. Twilio (TWLO) stock is climbing as Wall Street analysts grow increasingly optimistic about its artificial intelligence potential. Analysts anticipate improved profitability through the company's expanding generative AI capabilities, including conversational AI technologies. Texas Instruments (TXN) experienced a stock decline after issuing a weaker-than-expected profit forecast for the first quarter. This pullback occurred despite the company's fiscal fourth quarter results beating expectations on both revenue and earnings. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Angel Smith

Yahoo Finance Video 6 days ago

TWLO

TXN

NONOF
Novo Nordisk stock surges on trial results for injectable GLP-1

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin. Yahoo Finance senior health reporter Anjalee Khemlani breaks down these trial results and the position it gives Novo Nordisk in better competing with Eli Lilly's (LLY) newer emerging GLP-1 treatments. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 6 days ago

NONOF

NVO
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk announces new early clinical trial data for its latest weight loss drug, amecrytin.

Yahoo Finance 6 days ago

NONOF

NVO

LLY
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and

GlobeNewswire 6 days ago

NONOF

NVO
Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 10 days ago

TCEHY

TCTZF

LVMHF
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordi

TipRanks 12 days ago

NONOF

NVO

BMY
Medicare to negotiate prices on 15 drugs, including Ozempic

Medicare seeks to negotiate prices on 15 drugs, including Novo Nordisk's (NVO) GLP-1 weight-loss drugs Ozempic and Wegovy, in new talks. Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK) To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 13 days ago

PFE

MRK

AZN
Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

Investor's Business Daily 13 days ago

NONOF

NVO
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of unknowns.

Investor's Business Daily 13 days ago

NONOF

NVO

MRNA
Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

Novo Nordisk's (NVO) GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief. The last round of the Inflation Reduction Act (IRA) negotiations gave Medicare an average 22% price reduction for the drugs on this list. With $41 billion in annual Medicare spending on these drugs, the implications for healthcare costs — especially obesity treatments — are massive. However, questions loom around regulatory decisions under a new Trump administration, adding complexity to future outcomes. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Josh Lynch

Yahoo Finance Video 13 days ago

NONOF

NVO
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Yahoo Finance 13 days ago

AZN

AZNCF

TEVA
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adults with obesity. All treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a stati

GlobeNewswire 13 days ago

NONOF

NVO
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Investor's Business Daily 15 days ago

LLY

NONOF

NVO
Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected

Eli Lilly stock is down after issuing Q4 2024 guidance that missed Wall Street estimates.

Yahoo Finance 16 days ago

LLY

NONOF

NVO

Performance Overview

Return	NOVA.DU	OMX Copenhagen 25 Index
YTD	-2.38%	-0.51%
1-Year	-16.68%	-4.20%
3-Year	+99.28%	+2.11%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOVA.DU)

Novo Nordisk A/S - share repurchase programme

Trending tickers: Nvidia, Alphabet, Alibaba, Novo Nordisk and GSK

3 Intriguing Stocks That May Be Trading At An Estimated 13.8% Below Intrinsic Value

Stock Market Today: Indexes Close Near Day's Lows; Nvidia Ends Winning Streak, Tesla Reverses Lower (Live Coverage)

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Novo Nordisk, Twilio, Texas Instruments: Market Minute

Novo Nordisk stock surges on trial results for injectable GLP-1

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

Trending tickers: Trump Media, Intel, Alibaba, Novo Nordisk and Entain

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Medicare to negotiate prices on 15 drugs, including Ozempic

Novo Nordisk Dives After Medicare Targets Ozempic, Wegovy For Price Cuts

Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks

Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.

Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected

Performance Overview